Human-specific RNA analysis shows uncoupled epithelial-mesenchymal plasticity in circulating and disseminated tumour cells from human breast cancer xenografts.
Breast cancer (BC)
Circulating tumour cell (CTC)
Disseminated tumour cell (DTC)
Epithelial-mesenchymal plasticity (EMP)
Epithelial-mesenchymal transition (EMT)
Mesenchymal-epithelial transition (MET)
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
12
01
2019
accepted:
04
06
2019
pubmed:
14
6
2019
medline:
24
3
2020
entrez:
14
6
2019
Statut:
ppublish
Résumé
Blood samples, bone marrow, tumours and metastases where possible were collected from SCID mice bearing orthotopic xenografts of the triple-negative MDA-MB-468 cell line or a transplantable ER-positive patient derived xenograft (ED-03), and assessed using human-specific, tandem-nested RT-qPCR for markers relating to detection of circulating (CTCs) and disseminated tumour cells (DTCs), breast cancer clinicopathology, the 'cancer stem cell' phenotype, metabolism, hypoxia and epithelial-mesenchymal plasticity (EMP). Increased levels of SNAI1, ILK, NOTCH1, CK20, and PGR, and a decrease/loss of EPCAM in CTCs/DTCs were observed relative to the primary xenograft across both models. Decreased CD24 and EGFR was restricted to the MDA-MB-468 model, while increased TFF1 was seen in the ED-03 model. The major metabolic regulator PPARGC1A, and several hypoxia-related markers (HIF1A, APLN and BNIP3) were significantly elevated in both models. Increased expression of mesenchymal markers including SNAI1 was seen across both models, however CDH1 did not decrease concordantly, and several other epithelial markers were increased, suggesting an uncoupling of EMP to produce an EMP hybrid or partial-EMT. Single cell analysis of ED-03 CTCs, although limited, indicated uncoupling of the EMP axis in single hybrid cells, rather than distinct pools of epithelial or mesenchymal-enriched cells, however dynamic heterogeneity between CTCs/DTCs cannot be ruled out. Reduced CD24 expression was observed in the MDA-MB-468 CTCs, consistent with the 'breast cancer stem cell' phenotype, and metastatic deposits in this model mostly resembled the primary xenografts, consistent with the mesenchymal-epithelial transition paradigm.
Identifiants
pubmed: 31190270
doi: 10.1007/s10585-019-09977-y
pii: 10.1007/s10585-019-09977-y
doi:
Substances chimiques
RNA, Messenger
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-409Références
J Cell Physiol. 2000 Feb;182(2):269-80
pubmed: 10623891
Nat Rev Cancer. 2002 Aug;2(8):563-72
pubmed: 12154349
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42
pubmed: 12808139
J Cell Physiol. 2004 Aug;200(2):297-308
pubmed: 15174100
Int J Cancer. 2005 Apr 20;114(4):544-54
pubmed: 15551360
J Biol Chem. 2005 Mar 4;280(9):8094-100
pubmed: 15591043
Nat Rev Cancer. 2005 Aug;5(8):591-602
pubmed: 16056258
N Engl J Med. 2005 Aug 25;353(8):793-802
pubmed: 16120859
Clin Cancer Res. 2006 Oct 1;12(19):5615-21
pubmed: 17020963
Ann Oncol. 2008 Feb;19(2):308-14
pubmed: 17895257
Cancer Res. 2007 Oct 1;67(19):9066-76
pubmed: 17909010
J Clin Oncol. 2007 Nov 20;25(33):5287-312
pubmed: 17954709
Expert Rev Proteomics. 2007 Dec;4(6):741-56
pubmed: 18067413
J Cell Mol Med. 2008 Apr;12(2):374-90
pubmed: 18182063
Ann Oncol. 2008 Nov;19(11):1821-8
pubmed: 18550576
APMIS. 2008 Jul-Aug;116(7-8):552-68
pubmed: 18834402
Cancer Lett. 2009 Mar 8;275(1):35-43
pubmed: 18980801
Breast Cancer Res Treat. 2009 Dec;118(3):455-68
pubmed: 19115104
Nat Rev Cancer. 2009 Apr;9(4):265-73
pubmed: 19262571
Cancer Cell. 2009 Jul 7;16(1):67-78
pubmed: 19573813
Cancer Res. 2009 Oct 1;69(19):7860-6
pubmed: 19789350
Breast Cancer Res. 2009;11(6):R84
pubmed: 19919679
J Oncol. 2010;2010:617421
pubmed: 20016752
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Br J Cancer. 2010 Feb 2;102(3):561-9
pubmed: 20051957
Bone. 2011 Jan;48(1):37-43
pubmed: 20670698
Int J Cancer. 2012 Feb 15;130(4):808-16
pubmed: 21387303
Clin Cancer Res. 2011 May 1;17(9):2967-76
pubmed: 21415211
Breast Cancer Res. 2011 Jun 15;13(3):R67
pubmed: 21699723
Oncol Rep. 2011 Nov;26(5):1295-303
pubmed: 21785827
Nat Med. 2011 Sep 07;17(9):1048-9
pubmed: 21900919
Oncogene. 2012 Aug 16;31(33):3741-53
pubmed: 22120722
PLoS One. 2012;7(5):e33788
pubmed: 22586443
BMC Cancer. 2012 May 16;12:178
pubmed: 22591372
Cancer Metastasis Rev. 2012 Dec;31(3-4):469-78
pubmed: 22729277
Breast Cancer Res. 2012 Aug 15;14(4):R118
pubmed: 22894854
Clin Cancer Res. 2012 Oct 15;18(20):5701-10
pubmed: 22908097
Mol Cancer Ther. 2012 Nov;11(11):2526-34
pubmed: 22973057
Breast Cancer Res. 2012 Sep 19;14(5):R126
pubmed: 22992387
Nature. 2013 Jan 24;493(7433):487-8
pubmed: 23344357
Science. 2013 Feb 1;339(6119):580-4
pubmed: 23372014
Sci Transl Med. 2013 Apr 10;5(180):180ra48
pubmed: 23576814
Sci Rep. 2013;3:2560
pubmed: 23994953
Clin Chem. 2014 Jan;60(1):214-21
pubmed: 24255082
Br J Cancer. 2014 Jan 21;110(2):375-83
pubmed: 24366294
Stem Cell Reports. 2013 Dec 27;2(1):78-91
pubmed: 24511467
J Natl Cancer Inst. 2014 May 15;106(5):null
pubmed: 24832787
J Clin Oncol. 2014 Nov 1;32(31):3483-9
pubmed: 24888818
PLoS One. 2014 Jul 07;9(7):e101931
pubmed: 24999732
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
Nat Cell Biol. 2014 Oct;16(10):992-1003, 1-15
pubmed: 25241037
Cancer Res. 2015 Mar 1;75(5):892-901
pubmed: 25592149
Cancer Lett. 2015 May 1;360(2):213-8
pubmed: 25700777
Cancer Lett. 2015 Jun 28;362(1):36-44
pubmed: 25797316
Clin Cancer Res. 2015 May 1;21(9):2029-37
pubmed: 25896973
Cell Commun Signal. 2015 May 15;13:26
pubmed: 25975820
Oncotarget. 2015 Jun 20;6(17):15578-93
pubmed: 26008969
Int J Mol Med. 2015 Sep;36(3):733-8
pubmed: 26135903
J Pathol. 2016 Mar;238(4):489-94
pubmed: 26510554
Nature. 2015 Nov 26;527(7579):472-6
pubmed: 26560033
Sci Rep. 2015 Dec 03;5:17533
pubmed: 26631983
Int J Biochem Cell Biol. 2016 Jul;76:64-74
pubmed: 27163529
Cancer Res. 2016 Jul 15;76(14):4270-82
pubmed: 27221703
Biochem Biophys Res Commun. 2016 Sep 2;477(4):731-736
pubmed: 27353380
Cancer Metastasis Rev. 2016 Dec;35(4):645-654
pubmed: 27878502
J Mol Med (Berl). 2017 Feb;95(2):133-142
pubmed: 28013389
Oncogene. 2017 Jun 15;36(24):3417-3427
pubmed: 28092670
Mol Cancer. 2017 Jan 30;16(1):6
pubmed: 28137302
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):E2337-E2346
pubmed: 28270621
Dev Dyn. 2018 Mar;247(3):432-450
pubmed: 28407379
Nature. 2017 Jul 5;547(7661):E1-E3
pubmed: 28682326
Breast Cancer Res. 2017 Jul 27;19(1):86
pubmed: 28750639
Sci Rep. 2017 Nov 9;7(1):15140
pubmed: 29123322
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
Nature. 2018 Apr;556(7702):463-468
pubmed: 29670281
Gene. 2018 Sep 5;670:7-14
pubmed: 29802992
Lung Cancer. 2018 Oct;124:53-64
pubmed: 30268480
Nat Commun. 2019 Feb 15;10(1):766
pubmed: 30770823
Am J Pathol. 1998 Sep;153(3):865-73
pubmed: 9736035